Introduction
A DNA vaccine consists of a plasmid that allows expression of an antigen encoded by an inserted gene or cDNA in mammalian cells as directed by a strong promoter element, usually of viral origin (i.e., human cytomegalovirus, rous sarcoma virus). The first report that intramuscular (i.m.) injection of plasmid DNA could be used as a mode for vaccination sparked worldwide interest (1) . It has also been shown that other routes of DNA delivery such as intradermal (i.d.) injection (2) or facilitated transfer such as propulsion of DNA coated particles with a gene gun (3) would also result in expression of encoded antigens and induction of immune responses. DNA vaccines could be considered similar to viruses except that they are nonreplicating and lack the pathological consequences. Indeed, the immune response to a DNA vaccine mimics that of a viral antigen after infection (4, 5) with both cytotoxic T lymphocyte (CTL) and antibody (Ab) responses elicited.
The mechanism by which the DNA injected in saline enters the cells is unknown except that it is inefficient (compared to viral delivery) and may vary depending upon delivery method, as would the target cell population. I.m. injection results in low-level transfection of myocytes (6) whereas i.d. injection or gene gun delivery may directly transfect antigen-presenting cells (APCs) (2, 7) . There is one report of a very low level of macrophages that are transfected after i.m. injection (8) . Table 1 . Some of these advantages are due to properties inherent to DNA. The physiochemical stability and homogeneity of DNA should avail for easily produced inexpensive vaccines. Because DNA immunization is a form of in vivo transfection, the production of antigen will be in mammalian cells and antigens normally produced in such cells (e.g., viral protein) will thus be in native conformation. As in a viral infection, a broad (both cellular and humoral) immune response is induced. DNA vaccines may also be combined relatively easily, a feature that can be difficult for conventional recombinant vaccines in which protein solubility conditions differ. Overall, the advantages of DNA vaccines warrant the large research effort and expenditure, but the problems facing the technology will be difficult to overcome. In particular, there is a possibility the absence of adjuvant and contaminating proteins and, for example, could study immunity relevant to viral infection without the influence of viral biology (i.e., nonlytic, noninfectious). The absence of an antigen purification regimen could also potentially lead to easy production of monoclonal Ab for research and development programs (1 1, 12).
Ab reagents produced by DNA immunization could have the benefit of recognizing native or conformational determinants. This application has probably not been put to its full potential perhaps because of the need for a source of native antigen for screening. In this regard, it is worth considering the concept of original antigenic sin in immunology whereby the Ab response to a secondary immunization of a related antigen leads to primarily Abs of the primary specificity. Therefore, DNA immunization followed by bacterially derived recombinant antigen may reap the benefit of both-i.e., high Ab levels with native specificity.
For future vaccine candidate identification and development, DNA vaccines have the potential to simplify dramatically the production, purification, storage, and combination of different vaccines (Table 1 ). This could save enormous amounts of time and investment in evaluating vaccine candidate antigens in the laboratory and in producing vaccines ( Fig. 1) , as efficacy testing could commence in the order of weeks as opposed to months or even years for some recombinant proteins. An extreme example is expression library immunization (13) whereby the entire cDNA population or genome is used as a vaccine or as a starting point from which candidates could be identified via a process of elimination. This is more likely to be successful for screening pathogens with relatively small genomes. When compared to more conventional systems, the timesaving for large-scale evaluation of antigens is at least, in theory, enormous (Fig. 1) (18, 19) , while another investigated the CSP protein of Plasmodium falciparum (20) . The Calarota study (18) involved three groups of three subjects (HIV-1 infected but asymptomatic) who were each given three doses of 100 ,ug of plasmid encoding the cDNA for either nef, rev, or tat HIV-1 genes intramuscularly in distilled water. They reported that DNA vaccination induced detectable memory cells in all subjects and specific CTLs in eight out of nine subjects that were above preimmunization levels. However, three of these responses were transient. There were no apparent side effects reported.
In the MacGregor study (19) , three groups of five subjects (HIV-1 infected but asymptomatic) were given 30, 100, or 300 jig of plasmid DNA encoding modified env and rev HIV-1MN genes intramuscularly. No local or systemic reactions or laboratory abnormalities were seen and no anti-DNA antibodies were detected. Slight increases in antibody titers to recombinant HIV-1MN gpl20 and CTL were seen in some patients at the higher doses of plasmid DNA but no reduction in plasma HIV levels or CD4 or CD8 peripheral blood lymphocyte counts were apparent.
In the study by Wang et al. (20) , 20 healthy volunteers were given a DNA-based malarial vaccine encoding the P. falciparum circumsporozoite protein. Groups of five subjects were given three doses intramuscularly of either 20, 100, 500, or 2500 gg of DNA at four weekly intervals.
The vaccine was reported to be safe and well tolerated with the majority of subjects developing CTL responses in a dose-related manner. While the immunological responses in the published trials to date appear to have been modest, their initial focus has been on establishing the safety of DNA vaccine, and many subjects have been given low amounts of DNA, similar to what many experimenters have given to mice. In addition, the subjects in the HIV trials, while being asymptomatic, were HIV-1 infected, and this may have compromised their responses to DNA vaccination. The release of further human data from trials including those that have examined hepatitis B and influenza DNA vaccines is keenly awaited. It seems probable that strategies may need to be modified to achieve satisfactory human efficacy with DNA vaccines. These include modifications such as enhancing the uptake of DNA, targeting of the encoded proteins, or use of a prime-boost (DNA vaccine given in the initial dose followed by recombinant protein or virus).
Hurdles for DNA Vaccines
As mentioned earlier, gaining evidence to allay the safety concerns ( Figure 2 .
The addition of immunostimulatory sequences (CpG motifs) resulted in elevated Ab responses to DNA-encoded antigens following i.d. DNA injection (22, 23) . Another strategy was to use cytokines to influence the immune response. It was shown that when antigen-encoding DNA was co-injected with granulocyte-macrophage colony stimulating factor (GM-CSF), an enhanced Ab response was achieved, whereas the same strategy using interferon -y (INF-,y) decreased the Ab response (24) . Others have shown very modest enhancement of Ab responses to co-administered antigen due to GM-CSF (0.1 OD change at a serum dilution of 1:100) with no effect on the cellular response (25) . Furthermore, GM-CSF co-injection led to increases in seroconversion rates (percentage of mice testing positive for Ab responses) but not the magnitude of the Ab response (26) . Dramatic increases in antigen-specific CTL activity have been shown with co-administration of genes encoding interleukin (IL)-12 (25) or IL-2 (26). The enhancement achieved varies among systems and may therefore be somewhat dependent on the antigen. The mechanism by which cytokine gene transfer could augment antigen-specific immunity is unclear. Perhaps when the mechanisms in the immunobiology of DNA immunization are unraveled, approaches based on such rationale rather than empiricism will prove important.
An alternative to cytokine gene transfer in which cells of the immune system are the targets for activation is to modify the transfected cell. Myocytes lack co-stimulation and do not prime a CTL response directly after i.m. DNA injection. Instead, priming is achieved by nontransfected bone marrow-derived cells via a cross-presentation mechanism (27) (28) (29) . Co-injection of genes encoding the B7 co-stimulator molecules has been touted as a method to overcome this prob antigen-specific Ab responses after B7-1 co-delivery (30 (2, 35, 36) ]. Cellular localization of antigen had profound effects on immunity and it was shown that secreted antigen produced the highest Ab response. Anatomical localization of antigen also influenced the Ab response with i.d. injection proving to be the most potent route, presumably because of the large numbers of resident APCs. Interestingly, we found that injection into the spleen of mice produced an Ab response similar in magnitude to that of i.d. injection, even though there was dramatically less protein expression as determined using luciferase reporter (Table 2 ). Perhaps this is not surprising, as the secondary lymphoid organs are the sites of immune induction. This work led us to conclude that given the very small amounts of antigen expressed in muscle or dermis (<10 ng), the level of antigen reaching lymphoid organs may be limiting. Therefore, we designed a soluble fusion molecule between antigen and a ligand whose receptors are associated with lymphoid organs such that the immune response to the antigen could be dramatically increased (37) . Thus, different methods of varying antigen localization could be used to improve and influence the form of the immune response. 
Conclusions
The numerous potential advantages of DNA vaccination warrant further work, but the hurdles before this work remain formidable. In particular, regulatory concerns due to possible integration may restrict the widespread prophylactic use of DNA vaccines even if efficacy issues are overcome. The current human clinical trials may well answer some of these questions and we hope will suggest the continual development of DNA vaccines. In any event, DNA immunization has established itself as a useful tool for the research scientist and vaccine development program. The stunning successes in murine models demonstrate that DNA could be used to identify candidate antigens for more conventional vaccines and provide useful tools to understanding the immunology relevant to these models. Moreover, these models may eventually unravel the mechanisms of DNA uptake and immune induction. These mechanisms may then be manipulated for higher efficiency and thus efficacy in humans be augmented.
